Oncolytic immunotherapy biotech CG Oncology nabs $47M round for late-stage cancer push

Californian immuno-oncology biotech CG Oncology has reeled in a $47 million series D—and, surely, an IPO isn’t far behind—as it looks to phase 3 trials.

The funding was led by new investor Kissei Pharmaceutical with help from existing investors ORI Healthcare Fund, Camford Capital and Perseverance Capital Management.